New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel

Bandello, F.; Cunha-Vaz, J.; Chong, N. V.; Lang, Gabrielle E.; Massin, P.; Mitchell, P.; Porta, M.; Pruente, C.; Schlingemann, R.; Schmidt-Erfurth, U.

Erstveröffentlichung

2012

Metadata only
Search for full text

Wissenschaftlicher Artikel

Autoren

Bandello, F.

Cunha-Vaz, J.

Chong, N. V.

Lang, Gabrielle E.

Massin, P.

et al.

Institutionen

UKU. Klinik für Augenheilkunde

Erschienen in

Eye ; 26 (2012), 4. - S. 485-493. - ISSN 0950-222X

Link zur Veröffentlichung

https://dx.doi.org/10.1038/eye.2011.337

Förderinformationen

Novartis Pharma AG, Basel, Switzerland
Novartis Pharma AG
Allergan
Fovea Pharmaceutical
Sanofi Aventis
etc.

Schlagwörter

diabetic retinopathy; expert recommendations; vascular endothelial growth factor inhibitors; endothelial growth-factor; ranibizumab plus prompt; randomized-trial; intravitreal bevacizumab; deferred laser; risk-factors; triamcinolone; retinopathy; photocoagulation; complications

DDC-Sachgruppe

DDC 610 / Medicine & health

Metadata

Zur Langanzeige